R&D and Producer of Interventional Medical Devices for Heart Disease
Recently,Zhangjiang Hi-Tech Investment Enterprise HuiHe Healthcare Vispearl®The world's first full-size visible drug-loaded microsphere has received marketing approval from the National Medical Products Administration (NMPA). The microsphere is suitable for embolization treatment of hypervascular solid organ malignant tumors.
HuiHe Healthcare Vispearl®Is the world's first full-size visible drug-loaded microsphere, which is based on traditional drug-loaded microspheres and throughPatented iodine-containing contrast molecule (triiodobenzoic acid) combined with critical phase interface cross-linking process, produced this globally unique full-size visible drug-loaded microsphere. At the same timeSolved the pain points of traditional microspheres being too large for peripheral embolization and non-imaging post-operation.
It is reported that the development of the microsphere has been supported by the state-owned capital of Pudong.Zhangjiang Haoheng, a subsidiary of Zhangjiang Hi-Tech, participated in the D-round financing of HuiHe Healthcare in November 2022.HuiHe Healthcare is a globally innovative pan-vascular interventional enterprise, specializing in cardiac interventional valves, coronary and peripheral vessels, tumor intervention, and interventional robots, with over 200 patents. The core product, K-Clip, has successfully completed 250 surgeries in China, Europe, and the United States.It is reported that Tolerametinib (Koluping), the world’s first and only MEK inhibitor approved for marketing recently, targets NRAS-mutant advanced melanoma.®) The R&D company, Kezhou Pharmaceutical, also belongs to Zhangjiang Hi-Tech's Zhangjiang Haoke Investment enterprise.Zhangjiang Hi-Tech aims to "become a leading technology industry investment holding group" as its corporate vision, and in recent years has successively invested in leading companies in the fields of integrated circuits and biomedicine.